Clinical Trial Update: A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating upadacitinib (ABT-494) in Chinese and select countries' patients with moderately to severely active rheumatoid arthritis who had inadeq…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Upadacitinib (upadacitinib)

Snippet

Sponsor: AbbVie | Conditions: Rheumatoid Arthritis (RA) | Phase 3 | Status: COMPLETED | Results posted: 2020-08-06